During baseline testing of 111 subjects for a one-year, randomized, placebo-controlled, double-blind study, researchers confirmed that although the level of macular pigment, comprised of lutein and zeaxanthin from the diet, varied widely among subjects, it had a significant impact on glare disability, photostress recovery time, and contrast enhancement.
During baseline testing of 111 subjects for a one-year, randomized, placebo-controlled, double-blind study, researchers confirmed that although the level of macular pigment, comprised of lutein and zeaxanthin from the diet, varied widely among subjects, it had a significant impact on glare disability, photostress recovery time, and contrast enhancement.
The baseline testing was done for a trial, now in progress, to determine whether supplementing with Kemin LC’s and DSM’s FloraGLO lutein (10 mg/day) and DSM’s OptiSharp zeaxanthin (2 mg/day) leads to improved visual performance by increasing the level of macular pigment. The test tablets feature DSM’s Actilease technology to maximise the absorption of lutein and zeaxanthin.
The baseline testing results were presented in May at the Association for Research in Vision and Ophthalmology meeting in Fort Lauderdale, FL.
What's next for NPA and CRN in their complaints against New York state?
May 2nd 2024The latest updates in the efforts of the Natural Products Association and the Council for Responsible Nutrition to sue New York state for its law banning the sale of weight management and muscle building supplements to minors.